Results 51 to 60 of about 323,980 (248)

IONIC LIQUIDS DERIVATIVE OF 1Н-IMIDAZOLE AS NOVEL REAGENTS, CATALYSTS AND SOLVENTS [PDF]

Chemistry Journal of Moldova: General, Industrial and Ecological Chemistry, 2010
Ionic liquids are becoming widely used in chemical processes. Taking this into account we focus on recent advances in the synthesis and the investigation of 1H-imidazole derived ionic liquids.
V. Sargorovschi, N. Sucman, T. Iudin, D. Duca, E. Stingaci, D. Prodius, S. Pogrebnoi, F. Macaev   +7 more
doaj  

Influence of the molecular weight of polymer, solvents and operational condition in the electrospinning of polycaprolactone

Revista Facultad de Ingeniería Universidad de Antioquia, 2017
The objective of this study was to determine the influence of the molecular weight of polycaprolactone, solvents and operational conditions to obtain polymeric nanofibers by the electrospinning technique.
Gabriel Jaime Colmenares-Roldán, Yeixon Quintero-Martínez, Liliana María Agudelo-Gómez, Luis Fernando Rodríguez-Vinasco, Lina Marcela Hoyos-Palacio   +4 more
doaj   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane, Wei Xue, Amira Qumseya, Thomas Scharschmidt, Kathryn R. Tringale, Oscar Lopez Nunez, Jiaqi Hu, Donald A. Barkauskas, Rajkumar Venkatramani, Sheri L. Spunt, Aaron R. Weiss, Noah C. Federman   +11 more
wiley   +1 more source

Implementing Health‐Related Quality of Life Assessment in Pediatric Oncology: A Feasibility Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background There is growing interest in embedding health‐related quality of life (HRQoL) assessment and patient‐reported outcome measures (PROMs) within clinical cancer care. This study evaluated the feasibility, acceptability, and usability of implementing an electronic PROM (ePROM) platform to measure HRQoL in children with cancer ...
Mikaela Doig, Sophie Jessop, Jordan R. Hansford, Hien Le, Matthew O'Connor, Peter Gorayski, Andrew Cunningham, Amanda Hutchinson, Victoria Bedford, Eva Bezak, Nayana Parange, Kelly Skelton, Timothy Price, Michala Short   +13 more
wiley   +1 more source

Treatment Decision‐Making Roles and Preferences Among Adolescents and Young Adults With Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Decision‐making (DM) dynamics between adolescents and young adults (AYAs) with cancer, parents, and oncologists remain underexplored in diverse populations. We examined cancer treatment DM preferences among an ethnically and socioeconomically diverse group of AYAs and their parents.
Amanda M. Gutierrez, Jill O. Robinson, Wendy A. Allen‐Rhoades, Hadley S. Smith, Isabel Canfield, Rebecca L. Hsu, Sarah R. Scollon, Lauren R. Desrosiers‐Battu, Nicole M. Schneider, Frank Y. Lin, Donald Williams Parsons, Sharon E. Plon, Mary A. Majumder, Janet Malek, Amy L. McGuire   +14 more
wiley   +1 more source

Comparisons Between Different Crude Extract Yields Of Whole Plant Of Momordica Charantia And Their Antibacterial Susceptibility Against Selected Clinical Isolates

UMYU Journal of Microbiology Research, 2018
Medicinal plants such as Momordica charantia contained different phytochemicals which have antibacterial activity against Escherichia coli, Staphylococcus aureus, Pseudomonas fluorescens, Salmonella typhimurium and Klebsiella pneumoniae.
Oloninefa, S. D., Abalaka, M. E., Daniyan, S. Y., Mann, A.   +3 more
doaj   +1 more source

Parent Quality of Life at Two Years Following Their Child's Completion of Acute Lymphoblastic Leukemia Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Parents of children treated for acute lymphoblastic leukemia (ALL) often experience significant caregiver burden and disruption to their well‐being. While parent quality of life (QoL) during treatment is well characterized, little is known about outcomes during early survivorship.
Sara Dal Pra, Maria McCarthy, Michael Takagi, Cinzia De Luca   +3 more
wiley   +1 more source

Optimization of Growth Conditions of Serratia marcescens for Prodigiosin production

UMYU Journal of Microbiology Research, 2017
This study examined the optimization of growth conditions of Serratia marcescens isolated from a loamy soil of the Federal University Technology Minna Nigeria, for prodigiosin production.
Shaba, A. M., Oyeleke, S. B., Ijah, U. J. J., Oyewole, O. A., Adamu, B. B., Okeke, K. S., Baba, J., Cletus, C. I.   +7 more
doaj   +1 more source

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano, Alexander Yelak, Walid Kaadan, Shlomo Caduri, Rivka Friedland, Orli Michaeli, Gad Dotan, Osnat Konen   +7 more
wiley   +1 more source